TMB, MSI, and PD-L1 expression have been approved by the FDA for predicting the efficacy of ICIs in cancer patients, while PD-1 [26], CTLA-4 expression [27] and glycolysis score [28] have been reported as potential biomarkers for predicting response to ICIs therapy. This evidence concerns the gene CD274 and cancer.